• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Quotient Sciences

    Adare Pharma Solutions

    PCI Pharma Services

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Process Innovations: Who Should Lead & Their Impact?

    Who should lead and their impact?

    Process Innovations: Who Should Lead & Their Impact?
    Process Innovations: Who Should Lead & Their Impact?
    Related CONTENT
    • Bora Pharmaceuticals
    • Vetio Animal Health
    • So You Think You Know All About Excipients?
    • CROs & Next-Gen Drug Development
    • Aseptic Manufacturing Trends Roundtable
    Girish Malhotra, President, EPCOT International11.09.16
    Every business in every industry, whether it’s the financial services sector, the transportation industry, or the durables and consumer goods sector, as well as pharma, has to adhere to safety and product quality regulations. If regulators can point to oversights, errors and shortcomings, businesses have to fix their operations. To stay ahead, businesses must undergo the process of continuous improvement and innovation in order to compete in today’s business world.

    Modern pharma businesses have done an excellent job serving the global needs of patients for more than 100 years. However, their business model has remained relatively staid when it comes to process innovations in R&D and manufacturing. Sooner rather than later, the current model needs to be reconfigured and rejigged.1,2 This observation is fortified by a McKinsey & Co study.3 The opening paragraphs of the report were very telling five years ago when it was first published and, in my estimation, are still valid. Exhibits 2 and 3 of the report give us a snap shot of the industry and even though it is a bit out-of-date now, it revealed what has happened over the last ten years. We have seen the total number of generic companies have increased whereas the number of brand companies due to merger and acquisition (M&A) have decreased.

    A more recent report, “Generic medicines, the opportunity for growth,”4 projects generic drugs sales to 2019 and identifies the need for legacy drugs—infection, pain, cardiovascular and some chronic diseases—in countries outside the developed markets and also makes a very poignant remark about their affordability and access. It is true that drug prices outside developed countries are a fraction of what they are in developed countries, but even at those low prices they are unaffordable to much of the population.5

    I have used 80% (~5.8 billion)6 of the global population as the potential market size of individuals that have an increased need for pharmaceuticals. The remainder, about 1.4 billion, represents the population of developed countries. They have either government sponsored or mutually subsidized healthcare programs. Table 14 provides an illustration of generic drugs sales per million between developed and pharmerging countries.7 Since the generic sales for rest of the world (ROW) sales are not suggested in either report4,7 I have used an IMS report8 to increase ROW generic sales by 10%. 

    However, the numbers in Table 1 can be interpreted in many different ways. The following are some of my interpretations: 
    1. Sales per person per year in the developed countries—about 20% of the global population—are projected to be about 7.5 times higher than the pharmerging countries and about 12 times higher than the ROW.
    2. Total dollar sales in the developed countries are slightly more than three times higher than the pharmerging countries and 6.5 times of ROW sales.
    Low dollar sales per million in the pharmerging countries and ROW suggest there is a tremendous growth opportunity for generic drugs. Sales per day per person on a yearly basis in each category reveal an interesting number. Since sales are translated in dollar currency, numbers do not tell us the reality. This is because of varying purchase power parity of different currencies. However, they still point out that sales to a population of about six billion people could be higher if drugs were sold at more affordable prices.

    Pharmaceutical sales have been projected at $1.4 trillion for 2020.9 This represents significant sales growth in both brand and generics for every population segment. While global pharma sales will definitely increase, most of them will be through brand drugs for a very limited population in the developed countries and not through generic sales increase. Using projected generic sales for 20194 as a guide, I believe that 2020 global dollar sales projections9 are overly optimistic.10

    One fact we have to accept is that the brand new drugs will generally be sold in developed countries at much higher prices than the rest of the world. They are generally sold outside the developed markets either through licensing agreements or through WTO compulsory license (CL) provisions. Compulsory licensing is despised by brand pharma companies because it leads to big revenue losses. Drugs for AIDS suffered the wrath of CL. Gilead learned well from the AIDS drug debacle and sold HCV drugs through license agreement. Prices outside the developed countries are a fraction of developed country prices and still unaffordable to many.

    Generic sales shown in Table 1 reinforce the hypothesis that the prices in the developed countries are set at the highest level on the sentiment of extending life forever through government or mutually subsidized programs. Since actual prices are a mystery to most no one cares about them except when the drug prices dent family budgets as is happening with many drugs, too many to numerate here. 

    Low sales dollars outside the developing countries suggest that through better manufacturing technologies it is possible to make drugs more affordable. Point of affordability and value11 is repeatedly emphasized for the pharmaceutical industry’s success.

    It is well known that economies of scale result in better technologies that lower prices of the existing products and increase the customer base. Economies of scale also increase total sales and improve profits. I believe that pharmaceuticals could capitalize on this opportunity. 

    Process technologies in pharma
    One could ask why pharmaceuticals have not experienced or indulged in manufacturing innovation? My plausible answer is that the selling price of active pharmaceutical ingredients (APIs) and their formulations are a fraction of the actual drug-selling price and necessary investments in innovation do not provide financial justification. Brand companies have been able to charge the highest price for new drugs. Thus, during the short patent life, the need to optimize and lower manufacturing costs is not a priority for the brand companies.
    Generic producers have been able to make substantial monies by selling products in developed countries. Thus the need for cost reduction through process innovations has not existed. Since the same equipment is used for many products, financial justification for improvements could be challenging.

    Table 1 suggests that there are significant opportunities to increase sales outside the developed countries. However, there are significant roadblocks. They come from within pharma’s current business model. Readers should be very familiar with the current model but a quick review is helpful. 

    Big pharma’s focus mostly has been and is on new drugs. In recent years the focus of “Big” pharma has shifted from drugs for large masses (seven digits) to orphan drugs that are for small populations (five or low six digits) in the developed countries. These drugs are very high priced and are unaffordable to many even in the developed economies. Drugs (e.g. PCSK9 inhibitors) that are supposedly developed for large patient bases are also unaffordable. Their efficacy and performance compared to the existing drugs are questionable and have not delivered expected sales. Limited market results in lack of economies of scale do not help process innovation.

    Drugs when out of patent are produced by Generics. Generic producers use technologies and methods that are similar to what is used for brand drugs. Local generic producers make medicines for the local markets. The WTO TRIPS agreement changed the landscape. Due to high prices compared to the developing countries and ROW, the major focus of the generic companies located mostly outside the developed countries is to sell in the developed countries. There are many companies in the game. This has led to lack of economies of scale. The result is that there are many small producers and CMOs in the supply chain. Even with every effort to be the best, increased numbers of CMOs do not have the best of the best technologies. In addition, product changeovers and regulations can lead to multiple issues. 

    We need to recognize that drug dose—brand and generic—and the size of the patient base has a significant influence on the type of manufacturing methods that will be used for APIs and their formulations.10,12 As the global effluence increases the need for legacy drugs outside the developed world pharma sales would increase. But sales increase still would depend on affordability. If, through process innovation drug affordability can be improved and result in the additional sale of one-cent a day per drug per person outside the developed countries, additional revenue would be about $21 billion dollars per year, an unprecedented opportunity. Sustained yearly sales of $21 billion per year are equivalent to more than twenty blockbuster drugs per year, a windfall for Generics.

    For generic drugs depending on drug efficacy and effectiveness, API and their formulations can be produced by any of the following processing methods: Batch, Campaign batch, and Continuous.13

    Brand pharma could also use these options but their choices of technology due to market volume during the patent life are generally limited. Brands will essentially stay with batch process for APIs and their formulations. If the volume of a brand drug rises above a certain threshold they could move to “batch campaigns” provided the reactive chemistry for APIs and their formulations are similar. Product demand has to justify related investment for campaign batch or continuous processes.12,13 It is easier to say that we have or should have continuous or campaign batch processes in the manufacture of API and formulations but for that to happen, production volumes above certain threshold are needed. If the process equipment is used for less than 50% of the available yearly operating hours and is named a campaign batch or continuous, it would be really fudging the established definitions.

    If pharma is to cater to larger population then they have to make drugs affordable. This can only happen through lower medicine prices that will come from manufacturing process technology innovation. Larger manufacturing volumes generally would mean consolidation of CMOs and generics in API manufacture and formulations. Such a scenario might not sit well with many of the existing companies.

    One has to review supply and demand to think about consolidation. Consolidation generally changes the business model. Again, I believe if pharma companies want to cater to a larger global population base, they will have to make drugs affordable. Transition/evolution from the current model to a model that will cater to global needs is inevitable. It is waiting to happen. Speed and the timing of such an evolution is anyone’s guess.

    Mavericks similar to those who have caused a perturbation in high tech, biotech, genomics or diagnostics could be the movers and shakers in pharma also. Pieces and parts have been available but need to be put together differently.

    Physical properties and mutual behavior of the chemicals involved, created and blended during reactions and post reactions could be predicted and manipulated by algorithms and artificial intelligence to create products that are cheaper and their manufacturing processes are simpler and sustainable. Technology has to be such that it exceeds regulatory compliance needs. I would not be surprised if a creative genius at this moment is working in a garage to meet all of the expectations. The world population of about seven billion people and counting at every economic level14 would welcome process technology innovation, as it would lower healthcare costs. Even governments would welcome them. If they succeed they would make a dent in about a trillion plus dollar market in many different ways.

    Making drugs affordable through process technology innovation will have a lasting impact on pharma revenues and profits. Generics can lead the way and show what is possible. 

    References
    1. Christensen, Clayton M., Bartman, T., van Bever, Derek: The Hard Truth About Business Model, MITSloan Management Review, Fall 2016 Accessed October 5, 2016.
    2. Price II, W. Nicholson: Problems of Innovation-Deficient Pharmaceutical Manufacturing, The New England Journal of Medicine, November 23, 2013, Accessed February 5, 2015.
    3. Hunt, Vivian, Manson, Nigel and Morgan Paul: A Wake-up call for Big Pharma, McKinsey & Co., December 2011, Accessed September 28, 2016.
    4. Sheppard, Alan, Generic medicines, the opportunity for growth, CPhI 2016 Expert Report, pgs 55-59 Accessed September 28, 2016.
    5. Malhotra, Girish: Drug Prices: Food vs. Medicine – A Difficult Choice for Some, June 6, 2011, Accessed October 6, 2016.
    6. World Population http://www.infoplease.com/world/statistics/most-populous-countries.html, Accessed October 10, 2016.
    7. Hill, Raymond, Chui, Mandy: The Pharmerging Future, Pharmerging Executive, July 2009, Accessed October 10, 2016.
    8. The Global Use of Medicines: Outlook Through 2016, IMS Health, https://www.imshealth.com/files/web/IMSH%20Institute/Reports/The%20Global%20Use%20of%20Medicines%20Outlook%20Through%202016/Medicines_Outlook_Through_2016_Report.pdf, pg. 8, Accessed October 6, 2016.
    9. Global Medicines Use in 2020: Outlook and Implications, http://www.contractpharma.com/contents/view_experts-opinion/2016-09-27/manufacturing-processes-require-financial-justification/, Accessed October 6, 2016.
    10. Malhotra, Girish: Manufacturing technologies and their part to achieve future pharmaceutical, Chimica Oggi-Chemistry Today, Vol. 33(5), September/October 2016, pgs 28-31.
    11. Davis, Philip J: Affordability and Value-The Economics of Pharma’s New Science, https://www.accenture.com/us-en/insight-affordability-value-economics-pharma-new-science, Accenture Research, Accessed September 20, 2016.
    12. Malhotra, Girish: Manufacturing Processes Require Financial Justification, Contract Pharma, CPhI 2016 Annual Report, September 27, 2016, Accessed September 28, 2016.
    13. Malhotra, Girish: Pharmaceutical Processes: Batch or Continuous, Contract Pharma, September 23, 2016, Accessed October 6, 2016.
    14. Cone, Jason and Offenheiser, Raymond C., The U.S. Is Standing in the Way of Cheaper Drugs for the Poor, The New York Times, October 27, 2016 Accessed October 27, 2016.

    Girish Malhotra, president and founder of EPCOT International, has more than 45 years of industrial experience in pharmaceuticals, specialty, custom, fine chemicals, coatings, resins and polymers, additives in manufacturing, process and technology development and business development. girish@epcotint.com; Tel: 216-223-8763
    Suggested For You
    Bora Pharmaceuticals Bora Pharmaceuticals
    Vetio Animal Health Vetio Animal Health
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    CROs & Next-Gen  Drug Development CROs & Next-Gen Drug Development
    Aseptic Manufacturing Trends Roundtable Aseptic Manufacturing Trends Roundtable
    Reality and Un-Reality:  Continuous Processing in Pharmaceutical Manufacturing Reality and Un-Reality: Continuous Processing in Pharmaceutical Manufacturing
    DCAT Week DCAT Week '17 Q&A: API Market Trends
    The Good, the Bad, and the Donald The Good, the Bad, and the Donald
    The Search &  Rescue Mission for Data Integrity The Search & Rescue Mission for Data Integrity
    Manufacturing Processes Require Financial Justification Manufacturing Processes Require Financial Justification
    Contract Pharma 2016 Conference Photos Contract Pharma 2016 Conference Photos
    GDUFA I and GDUFA ll Present and Future Challenges GDUFA I and GDUFA ll Present and Future Challenges
    Manufacturing Processes Require Financial Justification Manufacturing Processes Require Financial Justification
    Continuous Pharmaceutical Processes and Their Demands Continuous Pharmaceutical Processes and Their Demands
    Tufts Report Evaluates R&D Efforts Tufts Report Evaluates R&D Efforts

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21


    • Preparing Your Post Pandemic Talent Strategy

      Preparing Your Post Pandemic Talent Strategy

      Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.
      Neil Kelly, Managing Partner, Vector Partners 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21

    • APIs | Supply Chain
      Securing Your API Supply Chain: Three Keys to Success

      Securing Your API Supply Chain: Three Keys to Success

      Key considerations when outsourcing API procurement and supply chain management.
      Selwyn Lustman and Lina Cogan, LGM Pharma 04.01.21


    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login